Delving into the Latest Updates on Beijing Sopuxingda Pharmaceutical Research Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Immune System Diseases

Hemic and Lymphatic Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Hemic and Lymphatic Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

DNA	1
5-HT2A receptor x D1 receptor x D2 receptor x hERG x α1A-AR x α1B-AR	1

Primary objective: To preliminarily explore the efficacy and safety of dicycloplatin injection in patients with mCRPC. Secondary objective: To evaluate the pharmacokinetic characteristics of dicycloplatin injection after multiple doses in patients with mCRPC and conduct an exploratory study on possible active metabolites.

Start Date-

Sponsor / Collaborator

Beijing Sopuxingda Pharmaceutical Research Co., Ltd.

[+1]

CTR20221306 / RecruitingPhase 3

TP21注射液用于TACE治疗肝细胞癌的有效性和安全性的随机、开放、平行对照、多中心Ⅲ期临床试验

[Translation] A randomized, open, parallel-controlled, multicenter phase III clinical trial to evaluate the efficacy and safety of TP21 injection in TACE treatment of hepatocellular carcinoma

主要目的：比较TP21与盐酸表柔比星用于TACE治疗不可切除肝细胞癌的有效性。次要目的：评价TP21用于TACE治疗不可切除肝细胞癌的安全性。

[Translation]

Primary objective: To compare the effectiveness of TP21 and epirubicin hydrochloride in TACE treatment of unresectable hepatocellular carcinoma. Secondary objective: To evaluate the safety of TP21 in TACE treatment of unresectable hepatocellular carcinoma.

Start Date29 Aug 2022

Sponsor / Collaborator

Beijing Sopuxingda Pharmaceutical Research Co., Ltd.

CTR20181994 / RecruitingPhase 2

TP21注射液用于TACE治疗肝细胞癌的有效性和安全性的随机、开放、平行对照、多中心探索性临床试验

[Translation] A randomized, open, parallel-controlled, multicenter exploratory clinical trial to evaluate the efficacy and safety of TP21 injection in TACE treatment of hepatocellular carcinoma

初步探索TP21用于TACE治疗肝细胞癌的有效性。以盐酸表柔比星为对照，比较TP21或TP21联合盐酸表柔比星用于TACE治疗肝细胞癌的疗效差异。次要目的：评价TP21用于TACE治疗肝细胞癌的安全性。

[Translation]

To preliminarily explore the effectiveness of TP21 in TACE treatment of hepatocellular carcinoma. Using epirubicin hydrochloride as a control, compare the efficacy of TP21 or TP21 combined with epirubicin hydrochloride in TACE treatment of hepatocellular carcinoma. Secondary purpose: To evaluate the safety of TP21 in TACE treatment of hepatocellular carcinoma.

Start Date15 Mar 2019

Sponsor / Collaborator

Beijing Sopuxingda Pharmaceutical Research Co., Ltd.

[+1]

100 Clinical Results associated with Beijing Sopuxingda Pharmaceutical Research Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Sopuxingda Pharmaceutical Research Co., Ltd.

Login to view more data

100 Deals associated with Beijing Sopuxingda Pharmaceutical Research Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Sopuxingda Pharmaceutical Research Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Approved

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Dicycloplatin ( DNA )	Small Cell Lung Cancer More	Approved
Thioridazine ( 5-HT2A receptor x D1 receptor x D2 receptor x hERG x α1A-AR x α1B-AR )	Hepatocellular Carcinoma More	Phase 3